SCHEMBL878070

SCHEMBL878070

Cn1nccc1B(O)OC(C)(C)C(C)(C)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17501187 0.83
SCHEMBL20744353 0.78 COMT (0.32)
SCHEMBL6840511 0.77 CYP1A2 (0.42)
SCHEMBL18420206 0.75 SSTR4 (0.32)
SCHEMBL31416574 0.74 SSTR4 (0.31)
SCHEMBL18282319 0.73 SMN1; SMN2 (0.31)
SCHEMBL15366138 0.73 DGAT1 (0.31)
SCHEMBL2261391 0.72
SCHEMBL1649419 0.71 CYP4F2 (0.41)
SCHEMBL16936890 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 420 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122036730-A Gαq/11 protein inhibitor with purine skeleton, and preparation method and application thereof 中山大学 2026-05-15 CN claimed
US-12258343-B2 Method for preparing 2-[(3R)-3-methylmorpholin-4-yl]-4-[1-methyl-1H-pyrazol-5-yl)-8-(1H-pyrazol-5-yl)-1,7-naphthyridine BAYER AKTIENGESELLSCHAFT (DE) 2025-03-25 US claimed
CN-112823158-B Process for preparing 2- [ (3R) -3-methylmorpholin-4-yl ] -4- (1-methyl-1H-pyrazol-5-yl) -8- (1H-pyrazol-5-yl) -1, 7-naphthyridine 拜耳股份有限公司 2023-08-15 CN claimed
EP-3841101-B1 METHOD FOR PREPARING 2-[(3R)-3-METHYLMORPHOLIN-4-YL]-4-[1-METHYL-1H-PYRAZOL-5-YL)-8-(1H-PYRAZOL-5-YL)-1,7-NAPHTHYRIDINE BAYER AG (DE) 2023-05-03 EP claimed
US-20210253573-A1 METHOD FOR PREPARING 2-[(3R)-3-METHYLMORPHOLIN-4-YL]-4-[1-METHYL-1H-PYRAZOL-5-YL)-8-(1H-PYRAZOL-5-YL)-1,7-NAPHTHYRIDINE BAYER AKTIENGESELLSCHAFT (DE) 2021-08-19 US claimed
EP-3841101-A1 METHOD FOR PREPARING 2-[(3R)-3-METHYLMORPHOLIN-4-YL]-4-[1-METHYL-1H-PYRAZOL-5-YL)-8-(1H-PYRAZOL-5-YL)-1,7-NAPHTHYRIDINE Bayer Aktiengesellschaft (DE) 2021-06-30 EP claimed
CN-112823158-A Process for the preparation of 2- [ (3R) -3-methylmorpholin-4-yl ] -4- (1-methyl-1H-pyrazol-5-yl) -8- (1H-pyrazol-5-yl) -1, 7-naphthyridine 拜耳股份有限公司 2021-05-18 CN claimed
WO-2020039025-A1 METHOD FOR PREPARING 2-[(3R)-3-METHYLMORPHOLIN-4-YL]-4-[1-METHYL-1H-PYRAZOL-5-YL)-8-(1H-PYRAZOL-5-YL)-1,7-NAPHTHYRIDINE BAYER AKTIENGESELLSCHAFT (DE) 2020-02-27 WO claimed
WO-2026102563-A1 DISUBSTITUTED PYRIMIDOPYRROLE ANALOG AND USE THEREOF 深圳湾实验室坪山生物医药研发转化中心 2026-05-21 WO disclosed
CN-122036730-A Gαq/11 protein inhibitor with purine skeleton, and preparation method and application thereof 中山大学 2026-05-15 CN disclosed
EP-4733303-A1 MUSCARINIC M4 RECEPTOR AGONIST AND USE THEREOF Haisco Pharmaceutical Group Co., Ltd. (CN) 2026-04-29 EP disclosed
EP-4729508-A1 TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA Arcus Biosciences, Inc. (US) 2026-04-22 EP disclosed
CN-121586717-A Heteroaryl compounds, process for their preparation and their use in medicine 江苏恒瑞医药股份有限公司 2026-02-27 CN disclosed
EP-4695236-A1 SUBSTITUTED PHENYL-PIPERAZINYL BASED MODULATORS FOR THE TREATMENT OF DISEASE Soley Therapeutics, Inc. (US) 2026-02-18 EP disclosed
EP-2178876-A1 SPIRO CONDENSED BARBITURIC ACID DERIVATIVES FOR USE AS ANTIBACTERIAL AstraZeneca AB (SE) 2010-04-28 EP disclosed
EP-2166846-A1 INHIBITORS OF JANUS KINASES Merck Sharp & Dohme Corp. (US) 2010-03-31 EP disclosed
WO-2010028174-A1 NOVEL BICCYCLIC COMPOUNDS AS GATA MODULATORS DR. REDDY'S LABORATORIES LTD. (IN) 2010-03-11 WO disclosed
WO-2009089508-A1 ACTIVATORS OF EXECUTIONER PROCASPASES 3, 6 AND 7 THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2009-07-16 WO disclosed
WO-2009010801-A1 SPIRO CONDENSED BARBITURIC ACID DERIVATIVES FOR USE AS ANTIBACTERIAL ASTRAZENECA UK LIMITED (GB) 2009-01-22 WO disclosed
WO-2008156726-A1 INHIBITORS OF JANUS KINASES MERCK & CO., INC. (US) 2008-12-24 WO disclosed